Psychedelic-Assisted Therapy

What Is Psychedelic-Assisted Therapy?

Psychedelic-assisted therapy is a clinical approach in which a psychoactive substance is administered in a controlled therapeutic setting — typically accompanied by psychotherapy sessions before, during, and after the drug experience. The goal is not to use the substance as a standalone drug but to use the altered state it produces as a catalyst for therapeutic insight, emotional processing, and lasting psychological change.

This distinguishes it from recreational use. In clinical trials and licensed therapeutic settings, dosing is supervised by trained clinicians, the environment is carefully controlled, and extensive psychological support accompanies the pharmacological experience.

How These Substances Work

Psilocybin (the active compound in "magic mushrooms") is converted in the body to psilocin, which is a serotonin 2A receptor agonistAgonist

A drug that binds to a receptor and activates it, producing a biological response that mimics the body's natural signaling molecules. Full agonists produce the maximum possible effect, while partial a

. Activation of 5-HT2A receptors in the prefrontal cortex and default mode network produces profound alterations in perception, thought, and sense of self. Brain imaging studies suggest psilocybin temporarily disrupts entrenched patterns of brain connectivity (including those associated with rumination and rigid negative thinking), potentially allowing new patterns to form.

MDMA (3,4-methylenedioxymethamphetamine) releases large amounts of serotonin, dopamine, and norepinephrine, producing feelings of emotional closeness, empathy, and reduced fear — without the perceptual distortions of classical psychedelics. This is thought to facilitate processing of traumatic memories without the high distress usually associated with trauma recall.

Ketamine is an NMDA receptor antagonistAntagonist

A drug that binds to a receptor but does not activate it, instead blocking the receptor and preventing agonists from producing their effect. Competitive antagonists can be overcome by higher concentra

that produces dissociative effects. At subanesthetic doses, it rapidly reduces depressive symptoms, often within hours — a distinct mechanism from conventional antidepressants that target serotonin or norepinephrine reuptake.

DEA Scheduling and Legal Status

In the United States, most psychedelics are Schedule I controlled substances under the Controlled Substances Act (DEA ScheduleDEA Schedule

The classification system used by the Drug Enforcement Administration to categorize controlled substances based on their accepted medical use and potential for abuse. Schedule I drugs (e.g., heroin) h

I = high abuse potential, no currently accepted medical use, lack of accepted safety for use under medical supervision). This designation makes clinical research difficult — researchers require DEA researcher registration, Schedule I manufacturing licenses for research materials, and DEA facility inspections.

• Psilocybin: Schedule I federally; legal for therapeutic use in Oregon (licensed service centers) and Colorado as of 2023–2024.
• MDMA: Schedule I federally; FDA rejected the first NDA submission in 2024 (see below) but trials continue.
• Ketamine: Schedule III; legally prescribable off-label. Esketamine (Spravato) is Schedule V and FDA-approved.
• LSD: Schedule I; early clinical research ongoing.

Ketamine and Esketamine

Ketamine is the only psychedelic-adjacent drug with broad clinical use today. It is administered off-label (as an IV infusion or oral lozenge) in ketamine clinics for treatment-resistant depression.

Esketamine (Spravato) — the S-enantiomer of ketamine, delivered as a nasal spray — received FDA approval in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation. It must be administered in a certified healthcare setting with a two-hour monitoring period due to risks of dissociation, sedation, and abuse potential.

Ketamine's antidepressant effect is rapid but often short-lived (days to weeks), necessitating repeated treatments.

Psilocybin Trials and Evidence

Multiple Phase 2 trials from Johns Hopkins, Imperial College London, and COMPASS Pathways have shown:

• Treatment-resistant depression: A single high dose of psilocybin (25 mg) produced significant and durable reductions in depression scores, with effects lasting weeks to months for many participants.
• Major depressive disorder: In a Johns Hopkins trial, two psilocybin sessions with psychotherapy produced large reductions in depression severity; 71% of participants showed a response at 4 weeks.
• Smoking cessation: Early trials show 80% abstinence at 6 months — remarkably high compared to standard cessation therapies.
• Alcohol use disorder: Reduced alcohol consumption and craving in Phase 2 trials.

Phase 3 trials (required for FDA approval) are underway. FDA granted psilocybin Breakthrough Therapy designation for treatment-resistant depression.

MDMA-Assisted Therapy for PTSD

MDMA-assisted therapy for PTSD was arguably the most advanced psychedelic application entering 2024. Phase 3 trials by MAPS (Multidisciplinary Association for Psychedelic Studies) showed that 67–71% of MDMA participants no longer met PTSD diagnostic criteria after treatment, versus 32–48% with placebo-plus-therapy.

However, the FDA rejected the NDA submission in August 2024, citing concerns about trial design (particularly blinding challenges — participants can usually tell they received MDMA), data integrity questions at one trial site, and requests for an additional Phase 3 trial. MAPS is working to address FDA concerns and re-engage with the approval process.

Risks and Serious Considerations

• Psychological distress during sessions: Difficult experiences ("bad trips") can occur even in supervised settings. Trained facilitators and careful patient selection mitigate but do not eliminate this.
• Contraindications: People with personal or family history of psychosis or bipolar I disorder are typically excluded from trials due to risk of precipitating psychotic episodes.
• Cardiovascular effects: MDMA raises blood pressure and heart rate; contraindicated in people with significant cardiovascular disease.
• Abuse potential: Though classical psychedelics are not considered physically addictive, MDMA has some addiction potential. Both carry risk of misuse outside clinical settings.
• Therapist misconduct: Reports of sexual abuse by therapists during MDMA sessions in some trials highlighted the vulnerability of patients in altered states and the need for strong oversight.

Key Takeaways

• Psychedelic-assisted therapy combines controlled substance administration with intensive psychotherapy, not simple drug prescription.
• Psilocybin (5-HT2A agonist), MDMA (serotonin/dopamine releaser), and ketamine (NMDA antagonist) work through distinct mechanisms.
• Ketamine/esketamine are the only approved options currently; esketamine (Spravato) has FDA approval for treatment-resistant depression.
• Psilocybin Phase 2 trials show strong results for depression and addiction; Phase 3 is underway.
• MDMA-assisted therapy for PTSD was rejected by the FDA in 2024 — further trials and regulatory engagement are ongoing.
• Serious risks include psychological distress, cardiovascular effects, and potential for therapist misconduct.